InterventionsHuman trial

HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc Analysis

ADA Scientific Sessions 2026 Abstract

The paper

Yeshaben Patel, Josh M. Noone, Chethana K. R, Chalak Muhammad

Chapel Hill

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Late-breaking 2843-LB

doi.org/10.2337/db26-2843-lb

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026